+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma



An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma



Annals of Oncology 24(12): 3065-3069



Treatment options for patients with nonbulky stage IA-IIA Hodgkin lymphoma include combined modality therapy (CMT) using doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) plus involved-field radiation therapy (IFRT), and chemotherapy with ABVD alone. There are no mature randomized data comparing ABVD with CMT using modern radiation techniques. Using German Hodgkin Study Group HD10/HD11 and NCIC Clinical Trials Group HD.6 databases, we identified 588 patients who met mutually inclusive eligibility criteria from the preferred arms of HD10 or 11 (n = 406) and HD.6 (n = 182). We evaluated time to progression (TTP), progression-free (PFS) and overall survival, including in three predefined exploratory subset analyses. With median follow-up of 91 (HD10/11) and 134 (HD.6) months, respective 8-year outcomes were for TTP, 93% versus 87% [hazard ratio (HR) 0.44, 95% confidence interval (CI) 0.24-0.78]; for PFS, 89% versus 86% (HR 0.71, 95% CI 0.42-1.18) and for overall survival, 95% versus 95% (HR 1.09, 95% CI 0.49-2.40). In the exploratory subset analysis including HD10 eligible patients who achieved complete response (CR) or unconfirmed complete response (CRu) after two cycles of ABVD, 8-year PFS was 87% (HD10) versus 95% (HD.6) (HR 2.8; 95% CI 0.64-12.5) and overall survival 96% versus 100%. In contrast, among those without CR/CRu after two cycles of ABVD, 8-year PFS was 88% versus 74% (HR 0.35; 95% CI 0.16-0.79) and overall survival 95% versus 91%, respectively (HR 0.42; 95% CI 0.12-1.44). In patients with nonbulky stage IA-IIA Hodgkin lymphoma, CMT provides better disease control than ABVD alone, especially among those not achieving complete response after two cycles of ABVD. Within the follow-up duration evaluated, overall survivals were similar. Longer follow-up is required to understand the implications of radiation and chemotherapy-related late effects. The trials included in this analysis were registered at ClinicalTrials.gov: HD10 - NCT00265018, HD11 - NCT00264953, HD.6 - NCT00002561.

(PDF emailed within 0-6 h: $19.90)

Accession: 051494047

Download citation: RISBibTeXText

PMID: 24121121

DOI: 10.1093/annonc/mdt389


Related references

Clinical trials report. Comparison of ABVD chemotherapy and a regimen including radiation therapy in patients with limited-stage non-Hodgkin's lymphoma. Current Oncology Reports 8(5): 354-357, 2006

Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. Journal of Clinical Oncology 23(21): 4634-4642, 2005

ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. New England Journal of Medicine 366(5): 399-408, 2012

Interim PET-directed therapy in limited stage Hodgkin lymphoma initially treated with ABVD. Haematologica 2018, 2018

Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome. Blood 118(17): 4585-4590, 2012

Patterns of disease progression and outcomes in a randomized trial testing ABVD alone for patients with limited-stage Hodgkin lymphoma. Annals of Oncology 18(10): 1680-1684, 2007

Limited stage grade 3 follicular lymphoma patients can experience favorable outcomes with combined modality therapy. Leukemia and Lymphoma 2019: 1-9, 2019

The case for combined-modality therapy for limited-stage Hodgkin's disease. Oncologist 17(8): 1006-1010, 2013

Interim positron emission tomography and clinical outcome in patients with early stage Hodgkin lymphoma treated with combined modality therapy. Leukemia and Lymphoma 54(6): 1183-1187, 2013

Combined modality consisting of chemotherapy and radiotherapy for limited stage histologically diffuse type non hodgkin's lymphoma of head and neck. Journal of Japan Society for Cancer Therapy 27(7): 1110-1119, 1992

Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. Journal of Clinical Oncology 11(11): 2258-2272, 1993

Chemotherapy or Combined Modality Therapy for Early-stage Hodgkin Lymphoma. Anticancer Research 38(5): 2875-2881, 2018

Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma. Zhonghua Zhong Liu Za Zhi 30(8): 630-634, 2010

Chemotherapy or combined modality therapy for early-stage Hodgkin lymphoma. Hematological Oncology 35: 315-315, 2017

Comparison of ABVD chemotherapy and a regimen including radiotherapy in patients with limited-stage Non-Hodgkins lymphoma. Current Oncology Reports 8(5): 355-356, 2006